Marinus Pharmaceuticals Crecimiento futuro

Future controles de criterios 5/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Marinus Pharmaceuticals de 67.6% y 34.9% respectivamente, mientras que el BPA crecerá en un 72.2% al año.

Información clave

67.6%

Tasa de crecimiento de los beneficios

72.2%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	19.5%
Tasa de crecimiento de los ingresos	34.9%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Good
Última actualización	14 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

BMV:MRNS * - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	71	-23	89	N/A	7
12/31/2025	51	-55	-40	N/A	10
12/31/2024	35	-116	-101	N/A	9
9/30/2024	31	-140	N/A	N/A	N/A
6/30/2024	30	-149	-121	-120	N/A
3/31/2024	28	-145	-114	-114	N/A
12/31/2023	31	-141	-118	-118	N/A
9/30/2023	31	-134	-113	-113	N/A
6/30/2023	26	-29	-119	-117	N/A
3/31/2023	22	-35	-128	-127	N/A
12/31/2022	25	-20	-115	-113	N/A
9/30/2022	20	-14	-115	-113	N/A
6/30/2022	28	-105	-80	-78	N/A
3/31/2022	28	-91	-69	-67	N/A
12/31/2021	15	-99	-58	-55	N/A
9/30/2021	15	-88	-52	-50	N/A
6/30/2021	5	-84	-71	-70	N/A
3/31/2021	4	-76	-63	-63	N/A
12/31/2020	2	-76	-61	-61	N/A
9/30/2020	0	-74	-61	-61	N/A
6/30/2020	N/A	-72	-58	-58	N/A
3/31/2020	N/A	-69	-51	-51	N/A
12/31/2019	N/A	-54	-49	-49	N/A
9/30/2019	N/A	-49	-42	-42	N/A
6/30/2019	N/A	-46	-37	-36	N/A
3/31/2019	N/A	-43	-34	-33	N/A
12/31/2018	N/A	-37	-28	-28	N/A
9/30/2018	N/A	-31	-23	-23	N/A
6/30/2018	N/A	-24	N/A	-19	N/A
3/31/2018	N/A	-19	N/A	-18	N/A
12/31/2017	N/A	-19	N/A	-19	N/A
9/30/2017	N/A	-20	N/A	-20	N/A
6/30/2017	N/A	-22	N/A	-24	N/A
3/31/2017	N/A	-27	N/A	-26	N/A
12/31/2016	N/A	-29	N/A	-25	N/A
9/30/2016	N/A	-30	N/A	-24	N/A
6/30/2016	N/A	-29	N/A	-23	N/A
3/31/2016	N/A	-25	N/A	-22	N/A
12/31/2015	N/A	-25	N/A	-20	N/A
9/30/2015	N/A	-21	N/A	-17	N/A
6/30/2015	N/A	-18	N/A	-14	N/A
3/31/2015	N/A	-17	N/A	-11	N/A
12/31/2014	N/A	-13	N/A	-9	N/A
9/30/2014	N/A	-12	N/A	-10	N/A
6/30/2014	N/A	-12	N/A	-8	N/A
3/31/2014	N/A	-11	N/A	-7	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que MRNS * sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (8.1%).

Beneficios vs. Mercado: Se prevé que MRNS * sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que MRNS * sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (34.9% al año) de MRNS * crezcan más rápidamente que los del mercado MX (7.2% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (34.9% al año) de MRNS * crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de MRNS * se prevé que sea elevada dentro de 3 años.

Marinus Pharmaceuticals Crecimiento futuro

Future controles de criterios 5/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Marinus Pharmaceuticals, Inc. Reaffirms Revenue Guidance for the Year 2024

Marinus Pharmaceuticals, Inc. Increases Earnings Guidance for Full Year 2024

Marinus Pharmaceuticals, Inc. Provides Earnings Guidance for 2024

Marinus Pharmaceuticals, Inc. Updates Revenue Guidance for the Fiscal Year 2023

Marinus Pharmaceuticals, Inc. Updates Revenue Guidance for the Fiscal Year 2023

Marinus Pharmaceuticals, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Recent updates

Third quarter 2024 earnings released: US$0.42 loss per share (vs US$0.61 loss in 3Q 2023)

New minor risk - Profitability

Marinus Pharmaceuticals Announces Topline Results from Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives

Marinus Pharmaceuticals, Inc. Reaffirms Revenue Guidance for the Year 2024

Marinus Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Marinus Pharmaceuticals Announces Ganaxolone Approves in China as First Treatment for Seizures Associated with CDKL5 Deficiency Disorder

Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) dropped from Russell Small Cap Completeness Index

Marinus Pharmaceuticals Announces Topline Results from Phase 3 Rise Trial of IV Ganaxolone in Refractory Status Epilepticus

Robbins LLP Files A Class Action Against Marinus Pharmaceuticals, Inc

Marinus Pharmaceuticals, Inc. Announces Key Business Updates for Tuberous Sclerosis Complex Program

Marinus Pharmaceuticals, Inc. Increases Earnings Guidance for Full Year 2024

Marinus Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024

New minor risk - Market cap size

Marinus Pharmaceuticals, Inc. Provides Update on the Phase 3 RAISE Trial

Marinus Pharmaceuticals, Inc., Annual General Meeting, May 22, 2024

Marinus Pharmaceuticals, Inc. Provides Earnings Guidance for 2024

Marinus Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 05, 2024

Marinus Pharmaceuticals, Inc. Announces Seven Presentations at AES 2023, New Publication in Epilepsia and Results from the Second Generation Formulation MAD Study

Marinus Pharmaceuticals, Inc. Updates Revenue Guidance for the Fiscal Year 2023

Marinus Pharmaceuticals, Inc. Updates Revenue Guidance for the Fiscal Year 2023

Marinus Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Second quarter 2023 earnings released: US$0.61 loss per share (vs US$1.06 loss in 2Q 2022)

Marinus Pharmaceuticals, Inc. Announces European Commission Approval of ZTALMY (Ganaxolone) Oral Suspension for Adjunctive Treatment of Epileptic Seizures Associated with CDKL5 Deficiency Disorder in Patients Two to 17 Years of Age

Marinus Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Marinus Pharmaceuticals, Inc. Receives Positive CHMP Opinion for ZTALMY®? (ganaxolone) for the Adjunctive Treatment of Seizures Associated with CDKL5 Deficiency Disorder

Marinus Pharmaceuticals, Inc. Appoints Sarah Noonberg as Member of the Board

Marinus Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 07, 2023

Marinus Pharmaceuticals, Inc. Appoints Steve Pfanstiel as Chief Operating Officer

Marinus Pharmaceuticals, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Marinus Pharmaceuticals, Inc. Announces Board Changes

Marinus Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $59.9979 million.

Marinus Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $59.9979 million.

Marinus Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Marinus Pharmaceuticals, Inc. Provides Revenue Guidance for the Fiscal Year 2022

Marinus Pharmaceuticals Announces U.S. Commercial Launch of ZTALMY (Ganaxolone) for Seizures Associated with CDKL5 Deficiency Disorder

Marinus Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) dropped from Russell 2000 Dynamic Index

Marinus Pharmaceuticals Expands Enrollment Criteria to Support Recruitment in Phase 3 RAISE Trial in Refractory Status Epilepticus

Marinus Pharmaceuticals, Inc. Announces Resumption of Phase 3 RAISE Trial in Status Epilepticus

Marinus Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 12, 2022

Marinus Pharmaceuticals, Inc. Announces Publication in the Lancet Neurology of Ztalmy® (Ganaxolone) Phase 3 Marigold Trial Results

Marinus Pharmaceuticals, Inc. announced that it has received $1.230085 million in funding

Marinus Pharmaceuticals, Inc. announced that it has received $30 million in funding from Oaktree Capital Management, L.P.

Marinus Pharmaceuticals, Inc. Announces Delay to RAISE Phase 3 Clinical Trial in Status Epilepticus and Associated IV Ganaxolone Clinical Trials

Marinus Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 21, 2022

Marinus Pharmaceuticals, Inc. Announces New Clinical and Research Data to Be Presented At American Epilepsy Society Meeting

High number of new directors

High number of new directors

Marinus Pharmaceuticals, Inc. Announces FDA Acceptance for Filing and Priority Review of New Drug Application for Ganaxolone in CDKL5 Deficiency Disorder

High number of new directors

European Medicines Agency Grants Marinus Pharmaceuticals Accelerated Assessment of Ganaxolone for Treatment of CDKL5 Deficiency Disorder

Marinus Pharmaceuticals, Inc. Announces Topline Data from Open-Label Phase 2 Trial Evaluating Safety and Efficacy of Adjunctive Oral Ganaxolone Treatment in 23 Patients with Seizures Associated with Tuberous Sclerosis Complex

Marinus Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for Ganaxolone for the Treatment of Seizures Associated with CDKL5 Deficiency Disorder and Provides Pipeline Update

High number of new directors

Forecast to breakeven in 2024

Marinus Pharmaceuticals Provides an Update on its Clinical and Regulatory Development Activities

Forecast to breakeven in 2024

Marinus Pharmaceuticals, Inc. Announces Executive Changes, Effective April 12, 2021

Revenue beats expectations

Marinus Pharmaceuticals, Inc. Unveils New Brand as the Company Prepares for Commercialization

Marinus Pharmaceuticals, Inc. to Report Q4, 2020 Results on Mar 09, 2021

Marinus Pharmaceuticals, Inc. Announces Agreement with Ceribell, Inc

Marinus Pharmaceuticals Receives Positive Response from FDA on Sufficiency of One Phase 3 Clinical Trial for Filing of New Drug Application for the Use of Ganaxolone in CDKL5 Deficiency Disorder

Marinus Pharmaceuticals, Inc. Appoints Christy Shafer as Chief Commercial Officer

Marinus Pharmaceuticals, Inc. Provides Corporate Update on Phase 3 RAISE Trial in Status Epilepticus

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura